EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MARCH 1, 2017
Media Advisory: To contact corresponding study author Chante Karimkhani, M.D., email Erika Matich at Erika.Matich@ucdenver.edu.
To place an electronic embedded link in your story: Links will be live at the embargo time: http://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2016.5538
How much do skin diseases contribute to the burden of disease worldwide?
A new article published online by JAMA Dermatology estimates the global burden of skin disease as measured by disability-adjusted life years or DALYs, with one DALY equivalent to one year of healthy life lost.
Skin diseases accounted for 1.79 percent of the global burden of disease as measured in DALYS from 306 diseases and injuries in 2013, with skin and subcutaneous diseases responsible for 41.6 million DALYS that year, according to the article by corresponding author Chante Karimkhani, M.D., of the University of Colorado, Denver, and Global Burden of Disease researchers and collaborators.
Data for the report were drawn from more than 4,000 sources including medical literature, population-based disease registries, hospital data, studies and autopsy data.
Skin diseases ranked in decreasing order by DALYS were: dermatitis (9.3 million DALYs), acne vulgaris (7.2 million DALYs), urticaria (hives, 4.7 million DALYs), psoriasis (4.7 million DALYs), viral skin diseases (such as viral warts, 4 million DALYs)), fungal skin diseases (3.8 million DALYs), scabies (1.7 million DALYs), melanoma (1.6 million DALYs), pyoderma and cellulitis (bacterial skin diseases, 1.1 million DALYs each), keratinocyte carcinoma (such as basal and squamous cell cancers, 820,000 DALYs), decubitus ulcer (bedsores, 660,000 DALYs) and alopecia areata (290,000 DALYs).
Skin and subcutaneous diseases were the 18th leading cause of DALYs worldwide in the Global Burden of Disease 2013 study and, excluding mortality, skin diseases were the fourth largest cause of disability worldwide, according to the article.
To read the full article, please visit the For The Media website.
(JAMA Dermatology. Published online March 1, 2017. doi:10.1001/jamadermatol.2016.5538; available pre-embargo at the For The Media website.)
Editor’s Note: The article contains conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email email@example.com.